On the Wednesday, January 28, 2026, episode of The Excerpt podcast: As GLP-1 use surges, lawsuits allege blindness, stomach paralysis and more. USA TODAY Investigative Reporter Austin Fast breaks down ...

X is putting its money where its mouth is. The Elon Musk-owned social media platform just pledged it will give $1 million to the user who creates the most popular long-form post using its newly ...

Once exclusively a treatment for diabetes, GLP-1 medications have gone mainstream — forcing restaurants to adjust to changing appetites and nutrition needs. As GLP-1 medications normalize smaller ...

Long-term GLP-1 use slows medical cost growth, according to findings published Jan. 13 from professional services firm Aon. The firm analyzed 192,000 GLP-1 users from July 2022 to March 2025, ...

Just when you thought the circular deals couldn’t get any more circular, OpenAI has invested in CEO Sam Altman’s brain computer interface (BCI) startup Merge Labs. Merge Labs, which defines itself as ...

On Thursday, OpenAI announced its investment in neurotech startup Merge Labs, cofounded by its CEO, billionaire Sam Altman. OpenAI will collaborate with the new venture to develop technology to link ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

Almost half of U.S. workers now report using artificial intelligence tools at work at least a few times per year, which steadily increased throughout 2025, according to a Dec. 14 report from Gallup.

KSN Skyview video of a wildfire burning north of Hutchinson around 1:30 p.m. Thursday. SpaceX explosion triggers emergencies 'Massive betrayal': Ghislaine Maxwell’s prison treatment sparks outcry ...

(RTTNews) - Clearmind Medicine Inc. (CMND), a clinical-stage biotech company developing psychedelic-derived therapeutics, has announced a reverse share split of its issued and outstanding common ...

Grounded in emerging science, Danone’s research and innovation team is developing nutrient-dense products tailored to every stage of the GLP-1 user journey – and meeting the needs of the broader ...

The World Health Organization (WHO) on Monday issued its first-ever global guidelines on the use of GLP-1 medications for treating obesity as a chronic illness. In a press release, the WHO said this ...